TELESIS BIO (TBIO)
(Delayed Data from NSDQ)
$4.38 USD
+0.55 (14.34%)
Updated Jul 10, 2024 03:59 PM ET
After-Market: $4.39 +0.01 (0.25%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
TBIO 4.38 +0.55(14.34%)
Will TBIO be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for TBIO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TBIO
Cytokinetics (CYTK) Reports Q4 Loss, Misses Revenue Estimates
Janux Therapeutics, Inc. (JANX) Reports Q2 Loss, Misses Revenue Estimates
TBIO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Telesis Bio (TBIO) Reports Q1 Loss, Misses Revenue Estimates
Emergent Biosolutions (EBS) Reports Q1 Loss, Tops Revenue Estimates
Beat the Market the Zacks Way: Hershey's, Telesis Bio, General Mills in Focus
Other News for TBIO
Biotech Alert: Searches spiking for these stocks today
12 Health Care Stocks Moving In Wednesday's Intraday Session
FFIE, OGEN and CCLD among mid-day movers
Telesis Bio in Jeopardy: Risks of Nasdaq Delisting and Financial Instability Loom
NOTV, BFRI and CPOP among pre-market losers